Haemonetics (HAE)
NYSE:HAE
Want to see HAE full AI Analyst Report?
Top Page
Haemonetics
(NYSE:HAE)
Select Model
Select Model
Rating:59Neutral
Price Target:
$68.00
▲(10.35% Upside)
Action:Reiterated
Date:05/08/26
The score is driven by fundamentally solid cash generation and constructive FY2027 guidance (revenue growth and margin expansion), tempered by 2026 margin compression and higher leverage. Technical indicators are the main near-term negative, with the stock in a broad downtrend despite oversold readings. Valuation is neutral-to-slightly expensive at a 26.2 P/E with no dividend support.
Positive Factors
Strong free cash flow generation
Consistent, material free cash flow (FCF) provides durable financial flexibility: it funds R&D and commercialization, supports opportunistic buybacks and debt repayment, and underpins the company’s ability to invest in consumable-led growth without needing equity issuance, improving long-term capital allocation.
Negative Factors
Elevated leverage and sticky debt
Higher leverage constrains financial flexibility and raises interest sensitivity, limiting the company’s ability to pursue large M&A or accelerate buybacks without increasing risk. Sticky debt levels elevate refinancing and covenant risk if cash flow weakens or rates rise, pressuring long-term strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow generation
Consistent, material free cash flow (FCF) provides durable financial flexibility: it funds R&D and commercialization, supports opportunistic buybacks and debt repayment, and underpins the company’s ability to invest in consumable-led growth without needing equity issuance, improving long-term capital allocation.
Read all positive factors
Haemonetics Key Performance Indicators (KPIs)
Any
Operating Income by Segment
Shows profit generated by each business unit, highlighting which segments contribute the most to the company’s bottom line and which consume investment. Helps investors see whether Haemonetics’ core operations are profitable, where margin improvement is possible, and how strategic choices or cost pressures affect overall earnings.
Shows profit generated by each business unit, highlighting which segments contribute the most to the company’s bottom line and which consume investment. Helps investors see whether Haemonetics’ core operations are profitable, where margin improvement is possible, and how strategic choices or cost pressures affect overall earnings.
Data provided by:
The Fly
The FlyHaemonetics (HAE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.98B
Dividend YieldN/A
Average Volume (3M)835.87K
Price to Earnings (P/E)26.2
Beta (1Y)0.59
Revenue Growth-1.97%
EPS Growth-38.95%
CountryUS
Employees3,657
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.04
Shares Outstanding45,445,984
10 Day Avg. Volume955,466
30 Day Avg. Volume835,865
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)3.20
Price to Sales (P/S)1.91
P/FCF Ratio9.79
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue2.97
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda11.72
Forecast
1Y Price Target
$73.71Price Target Upside19.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)5.22
Revenue Forecast (FY)$1.40B
Haemonetics Business Overview & Revenue Model
Company Description
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and softwa...
How the Company Makes Money
Haemonetics makes money primarily by selling proprietary medical devices and, more importantly, the recurring consumable disposables and supplies used with those devices. A core revenue engine is its plasma and blood collection franchise: the comp...
Haemonetics Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call presented multiple strong achievements: solid organic revenue growth (notably in plasma and blood management), full-year margin expansion, robust free cash flow and disciplined capital allocation, plus important product approvals and commercialization progress (Persona PLUS, VASCADE MVP XL and Vivasure acquisition). Notable near-term headwinds were acknowledged, including a weak interventional technologies performance, Q4 margin pressure driven by tariffs and transition effects, Vivasure dilution, and higher tax/interest costs. Management provided constructive FY2027 guidance (revenue growth and margin expansion), emphasized most large portfolio transitions are behind them, and outlined clear commercialization and launch plans. Overall, the positive operational and financial momentum and confident guidance outweigh the manageable near-term challenges.Positive Updates
Quarterly Revenue and EPS Growth
Q4 revenue of $346M, up 5% reported and 9% organic ex-CSL; adjusted EPS of $1.29, up 4% year-over-year.
Negative Updates
Interventional Technologies Weakness
Interventional technologies revenue declined 10% in Q4 and 9% for the full year; vascular closure was down 8% in the quarter with MVP and MVP XL volume pressured by EP share loss, OEM-related softness and procedure dynamics (PFA impacts on esophageal cooling also weighed on demand).
Read all updates
Q4-2026 Updates
Positive
Negative
Quarterly Revenue and EPS Growth
Q4 revenue of $346M, up 5% reported and 9% organic ex-CSL; adjusted EPS of $1.29, up 4% year-over-year.
Read all positive updates
Company Guidance
For fiscal 2027 management guided to reported revenue growth of 4%–7% (3%–6% organic, adjusted for the extra 53rd week and FX), with adjusted operating margin expanding 50–100 basis points year‑over‑year and adjusted EPS growing broadly in line with reported revenue (EPS guidance tied to reported growth including the 53rd week); they assume higher interest and an adjusted tax rate about 100 basis points above FY‑26, expect free cash flow conversion of ~80% (versus 89% in FY‑26), and built in a higher tariff assumption (15% vs ~10% currently) plus ERP costs and continued targeted investments. The guide includes a full year of Vivasure dilution (no associated revenue in the plan; Vivasure was roughly $0.05 dilutive in Q4, ~ $0.20 annualized) but excludes any revenue from PerQseal Elite; segment assumptions referenced mid‑single‑digit growth for plasma and hospitals, mid‑single‑digit decline for blood center, and gross‑margin improvement driven by plasma innovation, hospital mix and operating leverage.Haemonetics Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
54
Neutral
Cash Flow
70
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.33B | 1.36B | 1.31B | 1.17B | 993.20M |
| Gross Profit | 743.59M | 778.55M | 711.91M | 622.87M | 530.77M |
| EBITDA | 397.12M | 355.99M | 295.45M | 252.01M | 191.72M |
| Net Income | 97.31M | 167.68M | 117.56M | 115.40M | 43.38M |
Balance Sheet | |||||
| Total Assets | 2.40B | 2.45B | 2.20B | 1.93B | 1.86B |
| Cash, Cash Equivalents and Short-Term Investments | 245.44M | 306.76M | 178.80M | 284.47M | 259.50M |
| Total Debt | 1.22B | 1.22B | 807.79M | 765.89M | 780.78M |
| Total Liabilities | 1.60B | 1.63B | 1.24B | 1.12B | 1.11B |
| Stockholders Equity | 796.32M | 820.84M | 959.96M | 818.00M | 749.42M |
Cash Flow | |||||
| Free Cash Flow | 260.44M | 142.45M | 115.45M | 162.87M | 75.75M |
| Operating Cash Flow | 293.22M | 181.72M | 181.75M | 273.06M | 172.26M |
| Investing Cash Flow | -179.55M | -161.90M | -322.39M | -143.79M | -86.34M |
| Financing Cash Flow | -178.46M | 108.82M | 38.16M | -100.36M | -15.75M |
Haemonetics Technical Analysis
Positive
61.62
Price Trends
58.20
Positive
62.95
Positive
62.19
Positive
Market Momentum
0.57
Negative
67.33
Neutral
98.24
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Positive. The current price of 61.62 is above the 20-day moving average (MA) of 57.48, above the 50-day MA of 58.20, and below the 200-day MA of 62.19, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 67.33 is Neutral, neither overbought nor oversold. The STOCH value of 98.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HAE.
Haemonetics Risk Analysis
Haemonetics disclosed 37 risk factors in its most recent earnings report. Haemonetics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Haemonetics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $2.23B | 39.69 | 16.19% | 0.95% | 13.27% | 36.99% | |
68 Neutral | $3.83B | 25.02 | 8.95% | ― | 11.34% | 12.26% | |
59 Neutral | $2.98B | 26.20 | 11.32% | ― | -1.97% | -38.95% | |
57 Neutral | $3.33B | 26.54 | 2.19% | ― | -10.76% | ― | |
57 Neutral | $5.88B | -162.30 | -28.27% | 1.11% | -6.61% | -812.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $808.75M | -2.83 | -56.31% | ― | -3.87% | -258.96% |
* Healthcare Sector Average
HAE
Haemonetics
65.49
-0.57
-0.86%
ICUI
ICU Medical
133.31
4.32
3.35%
LMAT
Lemaitre Vascular
97.75
17.09
21.19%
MMSI
Merit Medical Systems
64.17
-31.21
-32.72%
QDEL
QuidelOrtho
11.86
-17.88
-60.12%
TFX
Teleflex
132.75
13.34
11.17%
Haemonetics Corporate Events
Executive/Board Changes
Haemonetics Announces Upcoming Departure of Longtime Board Director
Neutral
May 1, 2026
Haemonetics Corporation announced that longtime director Charles J. Dockendorff, who has served on its Board of Directors since 2014, notified the company on April 27, 2026, that he will not stand for re-election at the 2026 Annual Meeting of Shar...
Business Operations and StrategyPrivate Placements and Financing
Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure
Positive
Mar 3, 2026
On March 2, 2026, Haemonetics Corporation fully repaid at maturity its outstanding 0.00% Convertible Senior Notes due 2026, paying $300 million in cash equal to the principal amount. The company funded the repayment with cash on hand and borrowing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.